Lantheus (NASDAQ:LNTH) Sets New 52-Week High – What’s Next?

Lantheus Holdings, Inc. (NASDAQ:LNTH) hit a new 52-week high on Wednesday . The stock traded as high as $107.99 and last traded at $105.03, with a volume of 1423657 shares changing hands. The stock had previously closed at $104.67.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on LNTH. B. Riley Financial reissued a “buy” rating on shares of Lantheus in a report on Friday, May 1st. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $94.00 price objective on shares of Lantheus in a research report on Thursday, May 7th. Citigroup reiterated an “outperform” rating on shares of Lantheus in a research note on Friday, May 8th. Mizuho raised their target price on shares of Lantheus from $100.00 to $115.00 and gave the company an “outperform” rating in a report on Wednesday, May 27th. Finally, Truist Financial restated a “buy” rating and issued a $115.00 target price (up from $98.00) on shares of Lantheus in a research report on Monday, May 11th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $101.86.

Lantheus Stock Performance

The company has a current ratio of 2.83, a quick ratio of 2.64 and a debt-to-equity ratio of 0.47. The company has a market cap of $6.84 billion, a P/E ratio of 25.31 and a beta of -0.03. The company has a 50 day moving average price of $91.83 and a 200-day moving average price of $77.43.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.25 by $0.21. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The business had revenue of $377.33 million during the quarter, compared to the consensus estimate of $354.48 million. During the same period in the prior year, the company earned $1.53 EPS. Lantheus’s revenue for the quarter was up 1.2% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, equities analysts expect that Lantheus Holdings, Inc. will post 4.39 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lantheus

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Abel Hall LLC lifted its stake in Lantheus by 4.6% in the 1st quarter. Abel Hall LLC now owns 3,915 shares of the medical equipment provider’s stock valued at $297,000 after purchasing an additional 172 shares during the last quarter. Smartleaf Asset Management LLC lifted its stake in Lantheus by 63.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 197 shares during the last quarter. Blue Trust Inc. lifted its stake in Lantheus by 30.3% in the 4th quarter. Blue Trust Inc. now owns 990 shares of the medical equipment provider’s stock valued at $66,000 after purchasing an additional 230 shares during the last quarter. Vident Advisory LLC lifted its stake in Lantheus by 0.5% in the 4th quarter. Vident Advisory LLC now owns 44,763 shares of the medical equipment provider’s stock valued at $2,979,000 after purchasing an additional 230 shares during the last quarter. Finally, Farther Finance Advisors LLC lifted its stake in Lantheus by 71.4% in the 4th quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 275 shares during the last quarter. 99.06% of the stock is owned by institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.